BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:For more than two decades\, biopharma has struggled to develop
  safe and effective non-opioid pain therapies. With Vertex’s recent appro
 val marking a long-awaited breakthrough\, the momentum has reached a crit
 ical point for bringing non-opioid pain therapeutics to market.\n\nWhethe
 r advancing NaV-targeting drugs or pursuing novel pain mechanisms\, non-o
 pioid therapeutics are now in the clinical spotlight and the next 12 mont
 hs promise to be transformative.\n\nThe Non-Opioid Pain Therapeutics Summ
 it provides a dedicated platform to harness that momentum. Attendees will
  be learning from companies with approvals such as Tonix\, exploring late
 -stage strategies from innovators like Latigo and Algiax\, and uncovering
  discovery breakthroughs from Nocion and Axonis. Join 70+ discovery\, pre
 clinical\, translational and clinical industry-based experts driving the 
 future of non-opioid pain therapies across diverse pain indications.\n\n&
 nbsp\;\n\nURLs:Tickets: https://go.evvnt.com/3249980-1?pid=185&nbsp\;Broc
 hure: https://go.evvnt.com/3249980-3?pid=185&nbsp\;\n\nDate and Time: Tue
 \, 27 Jan 2026 09:00 - Thu\, 29 Jan 2026 15:00\n\nVenue details: The Colo
 nnade Hotel\, 120 Huntington Avenue\, Boston\, Massachusetts\, 02116\, Un
 ited States\n\nCategory: Conferences | Science\, Health &amp\; Medicine |
  Pharmaceuticals\n\nPrices:Drug Developer Pricing - Conference + Workshop
  Day: USD 3497.00\,Drug Developer Pricing - Conference Only: USD 2599.00\
 ,Academic Pricing - Conference + Workshop Day: USD 2897.00\,Academic Pric
 ing - Conference Only: USD 2199.00\,Service Provider Pricing - Conference
  + Workshop Day: USD 5097.00\,Service Provider Pricing - Conference Only:
  USD 3699.00\n\nSpeakers: Michele Curatolo\, Chief Medical Officer and Pr
 ofessor of Anesthesiology and Pain Medicine\, 4E Therapeutics and Univers
 ity of Washington\, Asli Chrisensen\, Director Search and Evaluation\, Ab
 bvie\, Guido Koopmans\, Chief Scientific Officer\, Algiax Pharmaceuticals
 \, Lizandra Marcondes\, Senior Vice President\, Medical Affairs and Drug 
 Safety\, Avertias Pharma\, Shane Hegarty\, Chief Scientific Officer\, Axo
 nis Therapeutics\, Clifford Woolf\, Director FM Kirby Neurobiology Centre
 \, Boston Children's Hospital\, Bryan Moyer\, Senior Vice President - Dis
 covery\, Latigo Biotherapeutics\, John Markman\, Vice President\, Global 
 Pain\, Eli Lilly and Co.\, Simon Westbrook\, Chief Scientific Officer\, L
 evicept\, Craig Granowitz\, Chief Medical Officer\, Lexicon Pharmaceutica
 ls\, Darrell Henze\, Executive Director\, Merck and Co\, Bruce Bean\, Pro
 fessor\, Neurobiology at Harvard Medical School\, James Ellis\, Chief Sci
 entific Officer\, Nocion Therapeutics\, Christopher Adams\, Executive Dir
 ector Search and Evaluation\, Novartis\, Heikki Mansikka\, Vice President
  Pain Therapy Areas\, Orion Pharma\, Hongkang Zhang\, Senior Director - P
 ain Therapeutic Lead\, Quiver Bioscience\, Gregory Sullivan\, Chief Medic
 al Officer\, Tonix Pharmaceuticals\, James Hackworth\, Chief Business Off
 icer\, Tris Pharma\, Jennifer Gewandter\, Associate Professor\, Universit
 y of Rochester Medical Center\n
DTEND:20260129T150000
DTSTAMP:20260512T214300Z
DTSTART:20260127T090000
LOCATION:The Colonnade Hotel\,  120 Huntington Avenue \, Boston\, Massachu
 setts\, 02116\,
SEQUENCE:0
SUMMARY:For more than two decades\, biopharma has struggled to develop saf
 e and effective non-opioid pain therapies. With Vertex’s recent approval 
 marking a...
UID:b029ceaf-7217-4b1c-af92-827aeb0765a4
END:VEVENT
END:VCALENDAR